Advertisement Banner
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy
No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy
No Result
View All Result
HealthNews
No Result
View All Result
Home Medicine

New Tablet Formulation of Calquence Approved for CLL, SLL, MCL

admin by admin
August 5, 2022
in Medicine


The Food and Drug Administration (FDA) has approved a new tablet formulation of Calquence (acalabrutinib) for all current indications, including adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 1 prior therapy.

The approval was based on data from the 3 open-label, single-dose, crossover, phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the currently marketed acalabrutinib 100mg capsules. The acalabrutinib tablets may be administered with proton pump inhibitors, antacids, and H2-receptor antagonists while the capsule formulation requires separating or avoiding the co-administration with these gastric acid reducing agents. 

The safety profile of the tablet formulation was mild with no new safety concerns identified. The most common adverse reactions (incidence at least 30%) for acalabrutinib are anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain.


Continue Reading

Calquence is currently available as 100mg capsules of acalabrutinib in 60-count bottles.

John C. Byrd, MD, Chair of the Department of Internal Medicine at the University of Cincinnati, said, “Patients with blood cancers like chronic lymphocytic leukemia and mantle cell lymphoma are often older and may face multiple medical conditions that may need intervention, including acid reflux or peptic ulcer disease. The US approval of acalabrutinib in a tablet form enables co-administration of the acalabrutinib tablet alongside a proton pump inhibitor.”

Reference

Calquence tablet formulation approved in the US across current indications. News release. AstraZeneca. Accessed August 5, 2022. https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-tablet-formulation-approved-in-the-us-across-current-indications.html

This article originally appeared on MPR

Topics:

Leukemias/lymphomas/ And Other Hematologic Cancers
Oncology



Source link

Advertisement Banner
Previous Post

Homeward secures $50 million in Series B funding and announces Priority Health partnership

Next Post

Cold Exposure A Possible Solution To Lose Weight Without Dieting

Next Post

Cold Exposure A Possible Solution To Lose Weight Without Dieting

Discussion about this post

Recommended

No survival benefit of resecting asymptomatic primary tumor

4 weeks ago

Is Balding Unavoidable? New Research Suggests Not

2 weeks ago

Don't Miss

Is the Latest Polio Scare Actually Caused by the Vaccine?

August 16, 2022

Apple Cider Vinegar for Weight Loss

August 16, 2022

Visibly receives FDA clearance for online visual acuity test

August 16, 2022

ABDM building comprehensive digital health ecosystem for country, Health News, ET HealthWorld

August 16, 2022

© 2022 Pharma News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy.

Navigate Site

  • News
  • Medicine
  • Health Tech
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.